XML 126 R98.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Arrangements - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 28, 2024
USD ($)
Jun. 29, 2022
USD ($)
Jun. 10, 2022
Oct. 01, 2021
USD ($)
Jul. 28, 2020
USD ($)
Jun. 11, 2020
USD ($)
obligation
Jan. 31, 2023
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jun. 30, 2024
USD ($)
Disaggregation of Revenue [Line Items]                          
Short-term contract liability                   $ 0 $ 2,311,000    
Long-term contract liability                   0 3,538,000    
Accounts receivable                   872,000 5,870,000    
Revenue recognized                   5,849,000      
Collaboration and license revenue                   38,275,000 26,004,000    
Remaining performance obligation                   $ 0      
Government Assistance Current Statement Of Financial Position Extensible Enumeration Not Disclosed Flag                   receivable      
Grant revenue                   $ 638,000 0    
National Institute of Neurological Disorders and Stroke of the National Institutes of Health Funding                          
Disaggregation of Revenue [Line Items]                          
Government assistance, award amount                         $ 1,500,000
Government assistance, potential additional award amount                         $ 1,500,000
Government assistance, asset, current                   600,000      
Grant revenue                   600,000      
SOBI Purchase Agreement                          
Disaggregation of Revenue [Line Items]                          
Sale common stock           $ 25,000,000              
Redemption premium         $ 14,500,000                
Astellas Gene Therapies                          
Disaggregation of Revenue [Line Items]                          
Collaboration and license agreements upfront payment             $ 10,000,000            
Development and commercial milestones plus royalties             $ 340,000,000            
Reimbursement percentage, budgeted costs incurred to complete the development             25.00%            
License and option agreement, development cost reimbursements             $ 5,500,000            
License and option agreement, written notice period before cancellation             90 days            
Short-term contract liability                   0 2,300,000    
Long-term contract liability                     3,500,000    
Accounts receivable                   100,000 300,000    
Customer, liability, revenue recognized, including opening balance                   6,300,000      
Revenue, remaining performance obligation recognized                   3,200,000      
Revenue recognized                     5,500,000    
Sarepta Therapeutics, Inc.                          
Disaggregation of Revenue [Line Items]                          
License and option agreement, written notice period before cancellation               30 days          
Short-term contract liability                   0 0    
Upfront cash payment               $ 2,000,000.0          
Sales milestone payments                 $ 3,000,000        
Collaboration and license revenue                   0 500,000    
Option term               24 months          
Extension term     9 months                    
Milestone receivable for certain dystrophies                       $ 2,000,000  
Milestone receivable                       $ 4,000,000  
Takeda Agreement                          
Disaggregation of Revenue [Line Items]                          
License and option agreement, written notice period before cancellation       90 days                  
Short-term contract liability                   0 0    
Contract with customer, asset, reclassified to receivable                     500,000    
Customer, liability, revenue recognized, including opening balance                   0 600,000    
Upfront cash payment       $ 3,000,000                  
Future additional payments, expected       $ 1,124,000,000                  
Collaborative Arrangement | Swedish Orphan Biovitrum AB (SOBI)                          
Disaggregation of Revenue [Line Items]                          
License and option agreement, written notice period before cancellation           180 days              
Accounts receivable                   100,000 4,600,000    
Revenue, remaining performance obligation recognized                   1,900,000 1,100,000    
Upfront cash payment           $ 75,000,000              
Sales milestone payments           $ 630,000,000              
Period after first commercial sale when the Company is eligible to receive royalties           10 years              
Number of obligations | obligation           3              
Development milestone           $ 5,000,000              
Collaborative arrangement, payment obligation   $ 10,000,000                      
Revenue recognized $ 30,000,000                 30,000,000      
Collaboration and license revenue                   31,900,000 19,400,000    
Collaborative Arrangement | Billed Revenues | Swedish Orphan Biovitrum AB (SOBI)                          
Disaggregation of Revenue [Line Items]                          
Accounts receivable                   $ 0 $ 3,000,000.0